Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors-Reference-Cited by-同舟云学术

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

Published:2017-09-30 Issue:3 Volume:36 Page:424-434
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Nishina Tomohiro,Takahashi Shunji,Iwasawa Ryota,Noguchi Hidehisa,Aoki Masayuki,Doi Toshihiko

Funder

Janssen Pharmaceutical K.K.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0514-4/fulltext.html

Reference36 articles.

1. Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437(2):199–213. https://doi.org/10.1042/BJ20101603

2. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Muller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26(10):2486–2497. https://doi.org/10.1002/jbmr.478

3. Razzaque MS (2009) The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5(11):611–619. https://doi.org/10.1038/nrendo.2009.196

4. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16(2):139–149. https://doi.org/10.1016/j.cytogfr.2005.01.001

5. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235–253. https://doi.org/10.1038/nrd2792

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial;BMC Cancer;2024-08-13

2. A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors;Investigational New Drugs;2024-06-04

3. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration;Current Cancer Drug Targets;2024-06

4. Low–dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model;Journal of Bone and Mineral Research;2024-04-09

5. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality;Acta Pharmaceutica;2024-03-01